FIELD: biotechnology.
SUBSTANCE: pharmaceutical composition containing APL type peptide identified as SEQ ID No.1, a sodium-acetate buffer solution with a pH value of 3.9-4.7, and stabilizing sugar, and its use are presented, as well as a method for the treatment of an inflammatory disease related to an increase in neutrophiles or citrullination of proteins.
EFFECT: invention allows for obtaining a pharmaceutical composition, which can be used for obtaining a drug for the treatment of inflammatory diseases related to an increase in neutrophiles or citrullination of proteins, such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), Alzheimer’s disease, as well as liver and lung fibrosis.
7 cl, 7 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEIN, PHARMACEUTICAL COMPOSITION, DRUG, DEVICE, KIT | 2019 |
|
RU2815577C2 |
| APPLICATION OF APL PEPTIDE FOR TREATMENT OF INFLAMMATORY INTESTINAL DISEASE AND TYPE 1 DIABETES | 2009 |
|
RU2524630C2 |
| NOVEL PEPTIDE-INHIBITOR PI3Kγ FOR TREATING RESPIRATORY DISEASES | 2015 |
|
RU2704826C2 |
| BLOCKING OF INFLAMMATORY PROTEASES BY THETA-DEFENSINS | 2012 |
|
RU2652605C2 |
| APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
| COMPOUNDS AND PHARMACEUTIC COMBINATIONS FOR TREATMENT OF NEURODEGENERATIVE AND ISCHEMIC BRAIN DISEASES | 2012 |
|
RU2569302C2 |
| COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF DISEASES, CONDITIONS, OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | 2012 |
|
RU2620066C2 |
| AMYLOID CONJUGATE, ITS APPLICATIONS AND METHODS | 2017 |
|
RU2712750C1 |
| METHODS OF REGULATING INFLAMMATION MEDIATORS AND PEPTIDES USED IN THEM | 2007 |
|
RU2429004C2 |
| INTEGRIN ανβ8 NEUTRALISING ANTIBODIES | 2011 |
|
RU2565539C2 |
